Skip to main content

Advertisement

Table 1 Clinical characteristics of the 179 DLBCL patients from 2006 to 2016

From: Prognostic significance of serum aspartic transaminase in diffuse large B-cell lymphoma

Characteristics No. of cases (%)
Age (years)
 ≤60 101 (56.4)
Male 104 (58.1)
Stage III-IV 99 (55.3)
Elevated ALT (>  50 U/L) 22 (12.3)
Elevated AST (>  33.3 U/L) 44 (24.6)
Elevated LDH (>  250 U/L) 72 (40.2)
ECOG PS ≥2 28 (15.6)
ENI ≥2 43 (24.0)
IPI score of 3–5 52 (29.1)
B symptoms 62 (34.6)
COO (Hans)
 GCB 77 (43.0)
Treatment
 R-CHOP 145 (81.0%)
 R-DA-EPOCHa 14 (7.8%)
 R-CHOP-likeb 20 (11.2%)
 Radiationc 11 (6.1%)
Auto-HSCT consolidationd 15 (8.4%)
  1. Abbreviations: ALT alanine aminotransferase, IPI International Prognostic Index, AST aspartate aminotransferase, COO cell of origin, DLBCL diffuse large B-cell lymphoma, ECOG PS performance status of Eastern Cooperative Oncology Group, ENI extra nodal involvement, GCB germinal-center B-cell type, HSCT Hematopoietic Stem Cell Transplantation, LDH lactate dehydrogenase
  2. aPatients with high risk (IPI = 4–5) received R-DA-EPOCH regimen
  3. bPatients with old age (≥ 75 years old), extremely poor ECOG PS or accompanying heart disease received R-CHOP-like regimens including R-CDOP, R-CEOP and R-mini-CHOP
  4. cCases with localized residual lesions received radiotherapy after immunochemotherapy
  5. dAmong the patients who received Auto-HSCT, 8 cases were AST positive